Timelines of Prostate Cancer Biomarkers

  • Gabriela Jurca
  • Omar Addam
  • Jon Rokne
  • Reda AlhajjEmail author
Part of the Lecture Notes in Social Networks book series (LNSN)


Prostate cancer is a deadly disease which affects men, yet there are few specific and sensitive biomarkers that can be used to diagnose and provide prognosis for the disease. Prostate specific antigen (PSA) is a serum protein that is one of the most well-established biomarkers in prostate cancer, but it lacks specificity and sensitivity. As a result, researchers are in search of other biomarkers such as genes or proteins that can be used for prostate cancer diagnostic test. In order to save effort, qualitative reviews based on primary studies are manually performed to characterize genes and proteins as emerging biomarkers. However, one problem is that less effective biomarkers might not be explicitly addressed as poor biomarkers in primary studies due to publication bias. We use text mining to provide a tool to examine whether biomarkers are emerging or decreasing in terms of publication popularity. In addition, we provide a tool to examine the increasing or decreasing popularity of gene families with respect to prostate cancer research. Selected biomarkers which have been labelled as emerging in qualitative reviews are evaluated using our approach. We also provide public access to our web portal to allow users to explore genes or gene families that they are interested in.


Prostate cancer Text mining Data mining 


  1. 1.
    Borgoño, C.A., Diamandis, E.P.: The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4(11), 876–890 (2004)CrossRefGoogle Scholar
  2. 2.
    Diamandis, E.P., Yousef, G.M.: Human tissue kallikreins: a family of new cancer biomarkers. Clin. Chem. 48(8), 1198–1205 (2002)Google Scholar
  3. 3.
    Draisma, G., Boer, R., Otto, S.J., van der Cruijsen, I.W., Damhuis, R.A., Schröder, F.H., de Koning, H.J.: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J. Natl. Cancer Inst. 95(12), 868–878 (2003)CrossRefGoogle Scholar
  4. 4.
    Economist: Time’s up. Economist 422(9033), 69–71 (2017)Google Scholar
  5. 5.
    Etzioni, R., Penson, D.F., Legler, J.M., di Tommaso, D., Boer, R., Gann, P.H., Feuer, E.J.: Overdiagnosis due to prostate-specific antigen screening: lessons from us prostate cancer incidence trends. J. Natl. Cancer Inst. 94(13), 981–990 (2002)CrossRefGoogle Scholar
  6. 6.
    Martin, S.K., Vaughan, T.B., Atkinson, T., Zhu, H., Kyprianou, N.: Emerging biomarkers of prostate cancer (review). Oncol. Rep. 28(2), 409–417 (2012)CrossRefGoogle Scholar
  7. 7.
    Nunes, T., Campos, D., Matos, S., Oliveira, J.L.: Becas: biomedical concept recognition services and visualization. Bioinformatics 29(15):1915–1916 (2013)CrossRefGoogle Scholar
  8. 8.
    Paliouras, M., Borgono, C., Diamandis, E.P.: Human tissue kallikreins: the cancer biomarker family. Cancer Lett. 249(1), 61–79 (2007)CrossRefGoogle Scholar
  9. 9.
    Parekh, D.J., Ankerst, D.P., Troyer, D., Srivastava, S., Thompson, I.M.: Biomarkers for prostate cancer detection. J. Urol. 178(6), 2252–2259 (2007)CrossRefGoogle Scholar
  10. 10.
    Prensner, J.R., Rubin, M.A., Wei, J.T., Chinnaiyan, A.M.: Beyond PSA: the next generation of prostate cancer biomarkers. Sci. Transl. Med. 4(127), 127rv3 (2012)CrossRefGoogle Scholar
  11. 11.
    Reed, A.B., Parekh, D.J.: Biomarkers for prostate cancer detection. Expert Rev. Anticancer Ther. 10(1), 103–114 (2010)CrossRefGoogle Scholar
  12. 12.
    Sardana, G., Dowell, B., Diamandis, E.P.: Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin. Chem. 54(12), 1951–1960 (2008)CrossRefGoogle Scholar
  13. 13.
    Stamey, T.A., Yang, N., Hay, A.R., McNeal, J.E., Freiha, F.S., Redwine, E.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317(15), 909–916 (1987)CrossRefGoogle Scholar
  14. 14.
    Velonas, V.M., Woo, H.H., Remedios, C.G.d., Assinder, S.J.: Current status of biomarkers for prostate cancer. Int. J. Mol. Sci. 14(6), 11034–11060 (2013)CrossRefGoogle Scholar
  15. 15.
    Vindrieux, D., Escobar, P., Lazennec, G.: Emerging roles of chemokines in prostate cancer. Endocr. Relat. Cancer 16(3), 663–673 (2009)CrossRefGoogle Scholar
  16. 16.
    Wang, M., Valenzuela, L., Murphy, G., Chu, T.: Purification of a human prostate specific antigen. Investig. Urol. 17(2), 159–163 (1979)Google Scholar
  17. 17.
    Xylogiannopoulos, K., Karampelas, P., Alhajj, R.: Discretization method for the detection of local extrema and trends in non-discrete time series. In: ICEIS 2015 - 17th International Conference on Enterprise Information Systems (2015)Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Gabriela Jurca
    • 1
  • Omar Addam
    • 1
  • Jon Rokne
    • 1
  • Reda Alhajj
    • 1
    Email author
  1. 1.Department of Computer ScienceUniversity of CalgaryCalgaryCanada

Personalised recommendations